No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY UK&IRELAND

Irish BioTech Aerska launches with €17 million to develop RNAi medicines for diseases of the brain

EU Startupsby EU Startups
October 1, 2025
Reading Time: 2 mins read
in UK&IRELAND, VENTURE CAPITAL
Share on FacebookShare on Twitter

Aerska, a Dublin-based BioTech company aiming to redefine the treatment of neurological diseases, today announced it has raised €17 million in Seed financing to develop systemically administered RNA interference (RNAi) medicines designed to silence genes that drive brain diseases.

The round was co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor), Norrsken VC, Kerna, PsyMed and Ada Ventures.

“Neurological diseases remain one of the greatest challenges in medicine, with limited options to alter the course of disease,” said Jack O’Meara, CEO & Co-founder, Aerska. “By integrating brain shuttles with RNA therapeutics, we aim to enable precise, durable gene silencing in the CNS; supported by technology to ensure patients get the right intervention for their stage of disease.”

Aerska was founded in 2025 by Jack O’Meara, Stuart Milstein and David Hardwicke and is launching with a leadership team with deep expertise in RNA medicines, CNS drug discovery, and clinical product development.

Aerska, named after a Gaelic proverb about “interdependence”, is headquartered in Dublin with research operations in London.

It is a BioTech company pioneering RNA medicines to treat, delay, and prevent diseases of the brain. The company is leveraging advances in ‘brain shuttles’ to enable targeted delivery of next-generation RNAi therapeutics to the CNS.

By silencing the genes that cause harm, Aerska aims to preserve the minds, protect the memories, and enable our loved ones to live longer, healthier lives.

“Delivery across the blood-brain barrier remains the bottleneck for genetic medicines in neurology,” said Alex Brunicki, Partner at Backed VC and Aerska board member. “Aerska’s platform integrates advanced RNAi chemistry with receptor-mediated shuttling and precision medicine, positioning the company at the forefront of CNS therapeutics.”

The company explains that delivering genetic medicines to the brain has long been hindered by the blood-brain barrier. While RNAi has proven effective in the liver, its potential impact in the CNS has been limited by delivery.

Through external partnerships and internal innovation, Aerska’s antibody-oligo conjugate (AOC) platform uses “brain shuttles” to enable systemic RNAi delivery, neuronal uptake, and durable gene knockdown in the brain. In addition, the company is making targeted investments in data science capabilities to advance a precision medicine strategy for neurology, starting with programmes in genetic forms of Alzheimer’s disease and Parkinson’s disease.

“GalNAc proved what RNAi can do when delivered to a specific tissue and we’re now on the cusp of a similar leap forward in CNS medicine,” said Stu Milstein, who leads platform strategy at Aerska. “The velocity and ambition of this team is electric.”

Read the orginal article: https://www.eu-startups.com/2025/10/irish-biotech-aerska-launches-with-e17-million-to-develop-rnai-medicines-for-diseases-of-the-brain/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

Vienna-based Optimuse raises €4 million seed round to scale AI-driven building engineering

October 1, 2025
FRANCE

French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis

October 1, 2025
FINTECH

London’s fan3 raises €4.2 million to address ticket reselling and scalpers

October 1, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Italian private equity accelerates, driven by add-ons. BeBeez reports.

Italian private equity accelerates, driven by add-ons. BeBeez reports.

September 7, 2025
AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

July 11, 2025
Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Next Post

London's fan3 raises €4.2 million to address ticket reselling and scalpers

French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart